Glaxo’s China woes deepen
GLAXOSMITHKLINE’S troubles in China deepened yesterday as state media in the country reported claims by authorities that the firm coordinated a programme of bribing medical staff.
The UK-based pharmaceuticals giant has said that any wrongdoing was committed by individual execs going against company policy.
But yesterday’s report by Xinhua said: “It is becoming clear that it is organised by GSK China rather than sales people’s individual behaviour.”
Senior Glaxo staff in China have been arrested over allegations of up to 3bn yuan (£315m) in bribes.
The firm said that the claims in yesterday’s report would be “a clear breach of our corporate values”.